InGel Therapeutics, Inc. — Form D
InGel Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2022-08-26. The offering totals $1.0M, of which $350K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-08-26
- Form: D
- Accession: 0001937613-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $1.0M
- Amount sold: $350K
- Remaining: $650K
- Investors: 4
- Date of first sale: 2022-07-06
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-457193
Issuer
- Name: InGel Therapeutics, Inc.
- CIK: 0001937613
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 27 MARNEY STREET, CAMBRIDGE, MA, 02141
- Phone: 617-949-0833
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Pierre Colombe Dromel | Director | Cambridge, MA |
| Deepti Colombe Singh | Director | Cambridge, MA |
| Myron Colombe Spector | Director | Cambridge, MA |
| Michael Colombe Young | Director | Cambridge, MA |
| Pierre Colombe Dromel | Executive Officer | Cambridge, MA |
More